Profile data is unavailable for this security.
About the company
Beijing Konruns Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of drugs. The Company's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Company’s present products under research include a range of innovative and generic drugs for tumors and blood. The Company mainly distributes its products in the domestic market.
- Revenue in CNY (TTM)874.20m
- Net income in CNY136.76m
- Incorporated2003
- Employees447.00
- LocationBeijing Konruns Pharmaceutical Co LtdNo. 3 Building, No. 7 YardKexueyuan Road, Zhongguancun LifeScience Park, Changping DistrictBEIJING 102206ChinaCHN
- Phone+86 1 082898898
- Fax+86 1 082898886
- Websitehttp://www.konruns.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shanghai OPM Biosciences Co Ltd | 265.48m | 40.29m | 3.74bn | 285.00 | 92.97 | 1.74 | -- | 14.09 | 0.3507 | 0.3507 | 2.31 | 18.70 | 0.1165 | 2.10 | 2.75 | 931,523.80 | 1.73 | 4.34 | 1.78 | 4.65 | 57.66 | 58.31 | 14.86 | 23.40 | 20.08 | -- | 0.0328 | 45.38 | -17.41 | 48.34 | -48.72 | -- | 6.09 | -- |
Tibet Weixinkang Pharmaceutical Co Ltd | 1.21bn | 243.48m | 3.81bn | 701.00 | 15.64 | 2.71 | -- | 3.16 | 0.5595 | 0.5595 | 2.77 | 3.22 | 0.6649 | 17.00 | 5.18 | 1,721,074.00 | 13.42 | 8.20 | 17.74 | 11.13 | 51.43 | 50.20 | 20.18 | 11.53 | 2.75 | -- | 0.0073 | 59.11 | -5.43 | 12.13 | 20.94 | 23.85 | -5.61 | 38.96 |
Jiangsu Aidea Pharmaceutical Co Ltd | 353.69m | -111.90m | 3.90bn | 476.00 | -- | 3.60 | -- | 11.04 | -0.2622 | -0.2622 | 0.8398 | 2.58 | 0.204 | 1.01 | 1.68 | 743,045.90 | -6.45 | -2.40 | -9.06 | -2.85 | 45.04 | 39.00 | -31.64 | -10.15 | 1.13 | -- | 0.281 | -- | 68.44 | 8.24 | 38.75 | -- | -4.47 | -- |
Beijing Konruns Pharmaceutical Co Ltd | 874.20m | 136.76m | 3.91bn | 447.00 | 28.24 | 1.24 | -- | 4.47 | 0.8643 | 0.8643 | 5.51 | 19.63 | 0.2293 | 1.82 | 3.01 | 1,955,707.00 | 4.50 | 5.43 | 5.31 | 6.24 | 88.30 | 89.93 | 19.62 | 20.76 | 2.93 | -- | 0.0435 | 21.53 | 6.15 | -2.08 | 48.24 | -10.63 | 43.05 | -9.71 |
Zhejiang Starry Pharmaceutical Co Ltd | 2.44bn | 31.85m | 3.96bn | 1.85k | 103.59 | 1.47 | -- | 1.62 | 0.0873 | 0.0873 | 6.75 | 6.16 | 0.4204 | 1.89 | 5.34 | 1,323,881.00 | 0.5588 | 3.30 | 1.13 | 5.97 | 22.38 | 32.35 | 1.33 | 8.21 | 0.6491 | 1.34 | 0.5201 | 53.08 | 3.04 | 19.78 | 158.32 | -13.94 | 10.39 | -- |
Hunan Warrant Pharmaceutical Co Ltd | 1.45bn | 211.90m | 4.13bn | 1.16k | 19.48 | 2.25 | -- | 2.85 | 2.26 | 2.26 | 15.46 | 19.58 | 0.6555 | 1.45 | 8.57 | 1,248,132.00 | 8.55 | 11.21 | 10.16 | 14.05 | 62.74 | 69.00 | 13.05 | 13.96 | 3.07 | -- | 0.0451 | 8.05 | 10.84 | 18.50 | 15.60 | 19.02 | 24.49 | -- |
Data as of Oct 11 2024. Currency figures normalised to Beijing Konruns Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
Holder | Shares | % Held |
---|---|---|
CITIC Securities Co., Ltd. (Invt Port)as of 31 Dec 2023 | 5.26m | 3.29% |
China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 2.06m | 1.29% |
Hwabao WP Fund Management Co., Ltd.as of 31 Dec 2023 | 1.07m | 0.67% |
Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 1.06m | 0.66% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 946.60k | 0.59% |
Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 733.00k | 0.46% |
HuaAn Fund Management Co., Ltd.as of 31 Dec 2023 | 520.80k | 0.33% |
China Asset Management Co., Ltd.as of 31 Dec 2023 | 495.80k | 0.31% |
Huatai-PineBridge Fund Management Co., Ltd.as of 31 Dec 2023 | 469.10k | 0.29% |
Broad Fund Management Co. Ltd.as of 31 Dec 2023 | 445.03k | 0.28% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.